UK NHS Pharmaceutical Approval Body Rejects GSK’s Lupus Drug Benlysta
Abstract:GSK’s new medicine for treating Lupus – Benlysta (generically known as ‘Belimubab’) was rejected by the UK National Health Service’s (NHS) drug rationing body. The drug was discovered by Human Genome Sciences and developed by Glaxo SmithKline (GSK) to combat the disease that causes the immune system to attack joints and organs. This article details why the drug was rejected and outlines the NHS drug approval process.
Trending Compliance Trainings
How FDA trains its investigators to review CAPA and what should you do to prepare
By - Jeff Kasoff
On Demand Access Anytime
By - Jeff Kasoff
On Demand Access Anytime
Excel Spreadsheets; Ensuring Data Integrity and 21 CFR Part 11 Compliance
By - David Nettleton
Live October 01, 2025
By - David Nettleton
Live October 01, 2025
Water System Investigation "How-To's" and Example Case Studies
By - T.C Soli
On Demand Access Anytime
By - T.C Soli
On Demand Access Anytime
QA Agreements for ISO 13485:2019 and other Regulatory Compliance
By - Betty Lane
On Demand Access Anytime
By - Betty Lane
On Demand Access Anytime
How to Achieve a Compliant and Effective Cleanroom Design and Facility Validation
By - Charity Ogunsanya
On Demand Access Anytime
By - Charity Ogunsanya
On Demand Access Anytime
Deciding When to Submit a 510(k) for a Change to an Existing Device - FDA's Final Guidance
By - Angela Bazigos
On Demand Access Anytime
By - Angela Bazigos
On Demand Access Anytime
You Recently Viewed
